Impact on Functional Status in Older Adults Treated With L-Carnitine

• Status: Unknown status
• Trial end date: 2017-09-30
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the impact of the treatment with L-Carnitine on the function of adults over 65 years, in conjunction with regular exercise. Simple randomization will be performed, distributing patients in 3 treatment groups, with L-Carnitine or Placebo, and with physical exercise at home or supervised.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hospital de Clínicas Dr. Manuel Quintela
• Collaborator: University of the Republic, Uruguay

Criteria

Inclusion Criteria:

• Patients who meet at least 2 criteria for the fragility phenotype of Linda Fried

• Ability to comply with aerobic physical activity of moderate intensity and basic resistance.

• Not depressed patients (Yesavage <5 in patients without previous depression or Hamilton <7 in patients in treatment for depression)

• MMSE (Mini-Mental State Examination) greater than 24 points.

• Independent or mildly dependent patients, Barthel> 95 points.

• Patients without visual disturbances or with decreased visual acuity corrected.

• No pain or with VAS (Visual analogue scale) <3/10.

• Patients without nutritional risk, MNA (Mini Nutritional Assessment > 23.5 / 30 points) and BMI (Body Mass Index) > 23 kg / m2.

Exclusion Criteria:

• Absolute contraindications for performing physical exercise: recent AMI or unstable angina, uncontrolled hypertension, acute HF and complete AV block.

• Patients with osteoarticular pathology that limits their physical activity.

• Previous neurological pathology (Stroke, Enf. Of Parkinson's).

• Acute or chronic diseases decompensated or with lymphedema that makes difficult the accomplishment of the bioimpedanciometry.

• Patients using orthopedic devices and prostheses or pacemakers that interfere with gait or impede the achievement of bioimpedanciometry.

• BMI less than 23 and / or an involuntary weight loss of 3kg or more in the last 3 months.

• Psychiatric disorders that hinder adherence to treatment.

• Moderate to severe Chronic Renal Disease

• Patient who does not agree to participate in the study.